Website
News25/Ratings0
News · 26 weeks28+400%
2025-10-262026-04-19
Mix1990d
- SEC Filings7(37%)
- Other5(26%)
- Insider4(21%)
- Leadership1(5%)
- Earnings1(5%)
- M&A1(5%)
Latest news
25 items- SECSEC Form PRE 14A filed by SCYNEXIS Inc.PRE 14A - SCYNEXIS INC (0001178253) (Filer)
- SECSCYNEXIS Inc. filed SEC Form 8-K: Leadership Update8-K - SCYNEXIS INC (0001178253) (Filer)
- SECSEC Form PRE 14A filed by SCYNEXIS Inc.PRE 14A - SCYNEXIS INC (0001178253) (Filer)
- INSIDERSEC Form 4 filed by Angulo Gonzalez David4 - SCYNEXIS INC (0001178253) (Issuer)
- SECSCYNEXIS Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - SCYNEXIS INC (0001178253) (Filer)
- PRPoxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 MillionPXL770, a first-in-class direct activator of adenosine monophosphate-activated protein kinase (AMPK), is a clinical-stage drug candidate targeting the underlying mechanisms of autosomal dominant polycystic kidney disease (ADPKD) by reducing cyst growth and disease progression Poxel will receive an upfront payment of $8 million, with an additional short-term payment of up to $8 million related to development milestones, and payments of up to $180 million related to commercial milestones A Phase 2 proof-of-concept study in patients with ADPKD is expected to begin in the fourth quarter of 2026, with a first efficacy review expected in the second half of 2027. Regulatory News: POXEL
- SECSCYNEXIS Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure8-K - SCYNEXIS INC (0001178253) (Filer)
- SECSCYNEXIS Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure8-K - SCYNEXIS INC (0001178253) (Filer)
- PRSCYNEXIS Announces $40.0 Million Private PlacementJERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) ("SCYNEXIS" or the "Company"), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors. The Company anticipates upfront gross proceeds from the private placement to be approximately $40.0 million, before deducting placement agent fees and transaction-related expenses, and up to an additional $52.2 million in gross proceeds if the Common Warrants a
- PRSCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progressionA Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027With this acquisition, SCYNEXIS strengthens its mission to develop innovative solutions for severe and rare diseases, unlocking further opportunities for value creation SCYNEXIS will host a conference call on March 31, 2026 at 8:30 a.m. ET to provide a corporate update. JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a
- PRSCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate UpdateSCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026 Responding to patients' need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years JERSEY CITY, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneerin
- SECSEC Form 10-K filed by SCYNEXIS Inc.10-K - SCYNEXIS INC (0001178253) (Filer)
- PRSCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247JERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the first participants have been dosed in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial evaluating the intravenous formulation (IV) of its second-generation triterpenoid antifungal therapy, SCY-247, which is being developed as a treatment for invasive candidiasis (IC) and as a prophylaxis therapy for invasive fungal disease. Results from this trial are expected in 2026. "Following the FDA's recent decision to grant SCY-247 bot
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.SCHEDULE 13G/A - SCYNEXIS INC (0001178253) (Subject)
- PRCERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of DirectorsSOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors. "Eric's decades of financial, transactional and operational experience will make an immediate impact to CERo's board of directors," said Chris Ehrlich, Company Chairman and Chief Executive Officer. "Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development." Mr. Francois is an executive with over 25
- INSIDERChief Financial Officer Macleod Ivor was granted 129,833 shares, increasing direct ownership by 48% to 398,529 units (SEC Form 4)4 - SCYNEXIS INC (0001178253) (Issuer)
- INSIDERChief Legal Officer Sukenick Scott was granted 129,833 shares, increasing direct ownership by 29% to 574,539 units (SEC Form 4)4 - SCYNEXIS INC (0001178253) (Issuer)
- INSIDERChief Executive Officer Angulo Gonzalez David was granted 391,333 shares, increasing direct ownership by 46% to 1,244,431 units (SEC Form 4)4 - SCYNEXIS INC (0001178253) (Issuer)
- PRSCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)JERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations highlighting data on the Company's second-generation fungerp drug candidate, SCY-247, at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI), which is taking place from January 28 to 30, 2026, in Las Vegas, Nevada. "We are pleased to participate in this important inaugural multidisciplinary meeting focused on addressing the significant threat of antimicrobial resistance," said David Angulo, M.D., Presi
- PRSCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant, Candida auris fungal infection JERSEY CITY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration ("FDA") has granted the Company Qualified Infectious Disease Product (QIDP) and Fast Track Designations for its second-generation triterpenoid antifungal therapy, SCY-247. "Receiving FDA's QIDP
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.SCHEDULE 13G/A - SCYNEXIS INC (0001178253) (Subject)
- PRSCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RequirementJERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market ("Nasdaq") to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2). The Company now has until June 15, 2026, to meet the requirement for its shares of common stock to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. Nasdaq granted the extension after determining that SC
- PRSCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSKGSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid single digit range JERSEY CITY, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the transfer of the BREXAFEMME (ibrexafungerp) New Drug Application (NDA) to GSK. "We are pleased to announce this important milestone for SCYNEXIS. With the transfer of the BREXAFEMME NDA now comple
- PRScynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal InfectionsFive-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company's next generation of triterpenoid antifungals (fungerps).Next-generation fungerps, in preclinical stages of development, are targeted to have enhanced pharmacological properties to treat fungal infections where current therapies are limited or not effective, while maintaining broad spectrum of activity against resistant fungal pathogens. JERSEY CITY, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent diff
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.SCHEDULE 13G/A - SCYNEXIS INC (0001178253) (Subject)